Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR61Clinical trial: Required

Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-25-449

Source: Grants.gov · View original posting ↗

Award
Amount not listed
Deadline
Jun 7, 2028
Letter of intent
Mechanism
R61
Duration
Expected awards
Funding cycle
Standard NIH dates
Open date
Sep 26, 2025
Total funding
Clinical trial
Required
GovernmentSmall businessHigher educationNonprofitForeign entities

Research areas

Basic mechanisms & biologyClinical trials

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

The National Center for Complementary and Integrative Health (NCCIH) announces this Notice of Funding Opportunity (NOFO) to solicit applications for research on how mind and body interventions through psychological and/or physical inputs (e.g., mindfulness meditation, yoga, acupuncture, massage, and other brain and/or body based interventions) impact mechanisms of emotional well-being (EWB) and their associations with whole person health (WPH), consistent with the NIH priority to address the health needs of the American people and improve their well-being. The NOFO will support rigorous and well-powered mechanistic research studies that are supported by strong preliminary data. The studies should examine the effects of mind and body interventions on innovative mechanisms of EWB (as the primary outcome), as well as the associated relationship with the Whole Person Health Index (WPHI, as a secondary outcome). To enhance research safety, rigor, and efficiency of NIH-funded mechanistic clinical trials, this initiative will use a two-phased award funding mechanism (R61/R33). The funding will support an initial phase (R61) to establish feasibility benchmarks for the proposed mechanistic clinical trial(s), followed by a second phase (R33) to complete the full-scale trials, which will be contingent upon successful completion of R61 milestones. Applications should provide preliminary data that are comparable in quality and quantity to those expected for an R01 proposal.

Data notes: award amount not published in the source feed; administering NIH institute could not be identified from the opportunity number.